Triad Isotopes

Triad Isotopes logo

Summary

Chief Restructuring Officer

Orlando, FL

Triad Isotopes was the second-largest radiopharmaceutical company in the United States, operating a nationwide network of cyclotrons and nuclear pharmacies strategically positioned to serve a broad range of healthcare providers. The company specialized in delivering nuclear medicine products for imaging, diagnosis, and disease treatment, as well as cyclotrons for advanced PET imaging. Triad catered to national group purchasing organizations, regional healthcare systems, independent clinics, and hospitals, playing a pivotal role in advancing nuclear medicine across the country.

The company faced declining margins due to competitive pressures, pricing challenges from national customers, rising costs from sole-source suppliers, and decreasing volumes. Carl Marks Advisors (CMA) was engaged to optimize the cost structure, enhance operational efficiency, and strengthen the company’s market position.

CMA negotiated more favorable supplier contracts, reducing price increases and mitigating bundling impacts, while repositioning the company to improve customer acquisition and retention. Additionally, CMA facilitated the acquisition of the market’s third-largest competitor, expanding the company’s national footprint, securing better supplier pricing, stabilizing market rates, and bolstering its ability to compete effectively.

 

Key Challenges
Supplier Cost Pressure
Customer Pricing Pressure
Competitive Market
Declining Volumes
Unfair Business Practices

Engagement Highlights

  • Evaluated the company’s cost structure, implementing strategies to reduce costs and effecting initiatives to make the company the most efficient operator in the market.
  • Leveraged business relationships and market knowledge to negotiate more favorable contracts with suppliers to minimize price increases and abate the impact of bundling.
  • Repositioned the company’s market standing to improve customer hit and retention rates, while minimizing margin erosion.
  • Facilitating the M&A process of acquiring the number three competitor in the market, enabling the company to increase national footprint, acquire favorable pricing from proprietary manufacturers, stabilize market pricing, and better compete for market share.

Sign Up for Our Newsletter

Name(Required)
This field is for validation purposes and should be left unchanged.